Tyme Technologies, Inc. (NASDAQ:TYME) Q4 2020 Earnings Conference Call - Final Transcript
May 20, 2020 • 05:00 pm ET
Good evening and welcome to Tyme's Fourth Quarter and Fiscal Year 2020 Investor Conference Call. I'd like to remind you that this call is being recorded.
I'd now like to turn the call over to Brian Gill, Corporate Communications and Investor Relations for Tyme.
Thanks, Daniel and welcome everyone to our Fourth Quarter and Fiscal Year 2020 Investor Conference Call. The press release reporting our financial and operating results can be accessed by going to the Investor Relations section of Tyme's corporate website at www.tymeinc.com.
Joining me today with prepared remarks are our Chairman and Chief Executive Officer, Steve Hoffman; our President and Chief Financial Officer, Ben Taylor; our Chief Operating Officer, Michele Korfin; our Chief Medical Officer, Dr. Giuseppe Del Priore; and our Chief Business Officer, Dr. Jonathan Eckard.
As a reminder, during today's call, we will be making forward-looking statements regarding our financial and operational outlook in addition to regulatory and product development plans. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent 10-K to be filed with the SEC. These statements speak only as of today's date, and we specifically disclaim any obligation to update or revise them.
I'd now like to turn the call over to our Chairman and Chief Executive Officer, Steve Hoffman.
Thank you, Brian. Good afternoon and thanks for joining us today. In fiscal 2020, our fourth full year as a public company, Tyme delivered extraordinary results, culminating with the launch of our first pivotal trial that will evaluate SM-88 for patients with third-line pancreatic cancer. Our highest corporate priorities for 2020 were, to present our growing body of clinical data at major international medical meetings, initiate pivotal studies in second- and third-line pancreatic cancer, expand clinical study programs into sarcomas, ensure capital resources that better position Tyme to carry out its pivotal trial, and advance planning for clinical trials in metastatic breast, prostate and hematological cancers, as well as continue to develop preclinical and mechanism data studies.
We anticipate multiple catalysts and drivers of value in fiscal year 2021, including the release of new preclinical SM-88 and TYME-18 data. We truly believe that our accomplishments demonstrate our leadership position in this emerging class of cancer metabolism based therapies.
I'd like to take a moment and discuss the effect of COVID-19 on Tyme and our ability to continue pursuit of our objectives. Tyme has developed techniques to allow its executives to maintain uninterrupted pursuit of responsibilities and duties, as well as incorporated adaptations to continue group and committee endeavors. We have also inventoried sufficient clinical supplies like drug product to allow us to serve patients in our trials. It is important to note that our clinical trials have been minimally affected by the COVID crisis. This is in part because of the essential nature of treatment in third-line pancreatic cancer and sarcoma and because we offer an oral drug that can be taken